Thrivent Financial for Lutherans Sells 310,108 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Thrivent Financial for Lutherans decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 56.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 235,057 shares of the company's stock after selling 310,108 shares during the period. Thrivent Financial for Lutherans' holdings in Elanco Animal Health were worth $2,846,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ELAN. JPMorgan Chase & Co. grew its stake in shares of Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company's stock worth $147,747,000 after purchasing an additional 4,361,799 shares during the last quarter. Brandes Investment Partners LP increased its holdings in shares of Elanco Animal Health by 66.9% in the fourth quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company's stock valued at $69,405,000 after buying an additional 2,296,691 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Elanco Animal Health in the third quarter valued at $19,708,000. Private Management Group Inc. boosted its stake in shares of Elanco Animal Health by 63.4% during the 4th quarter. Private Management Group Inc. now owns 2,357,142 shares of the company's stock worth $28,545,000 after acquiring an additional 914,808 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Elanco Animal Health during the 4th quarter worth $10,561,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the purchase, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.57% of the stock is owned by insiders.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded down $0.26 during trading on Monday, reaching $10.15. The stock had a trading volume of 195,808 shares, compared to its average volume of 4,770,897. The stock has a fifty day simple moving average of $11.23 and a two-hundred day simple moving average of $12.42. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 52 week low of $10.03 and a 52 week high of $18.80. The firm has a market capitalization of $5.02 billion, a price-to-earnings ratio of 25.39, a P/E/G ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the business earned $0.08 EPS. The business's revenue was down 1.4% compared to the same quarter last year. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on ELAN shares. Stifel Nicolaus reduced their target price on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. Morgan Stanley reduced their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a research report on Monday, December 2nd. Piper Sandler decreased their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Finally, Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of "Hold" and an average price target of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.